Introduction
Squamous cell carcinomas (SCCs) are the most common forms of human cancer (1) and are a major cause of death. These heterogeneous tumors originate from surface epithelia, such as skin and aerodigestive and urogenital tracts, in response to a variety of noxious conditions (1) . Common gene alterations are found in these tumors, distinguishable in 2 main categories: mutations with driver function in many cancer types and more selective mutations affecting squamous cell-fate commitment and/or ensuing terminal differentiation (1) .
Notch signaling is an important form of direct cell-cell communication with an essential role in the switch between proliferation and differentiation of keratinocytes (2) . It impinges on direct regulators of proliferative potential, such as p21WAF1/Cip1 (3) and p63 (4) , as well as more indirect paracrine mechanisms involved in normal skin homeostasis and barrier function (5) (6) (7) . This pathway plays a similarly important role in oral (8) , esophageal (9) , bronchial (10) , and cervical epithelia (11) .
Inactivating mutations of NOTCH1, NOTCH2, and NOTCH3 receptor genes are frequently found in SCCs from various body sites (1) . Of these, NOTCH1 plays a prominent role in SCC suppression. In addition to being frequently mutated, this gene is a direct positive target of p53 in keratinocytes and is commonly downmodulated as a consequence of compromised p53 function in SCC cells (12, 13) .
In spite of its highly context-dependent functions, "canonical" Notch signaling has been highly conserved throughout evolution, with translocation of activated Notch intracellular domain into the nucleus, converting the DNA-binding protein CSL (RBP-Jκ) from a repressor into an activator of transcription (14) . While functioning as an essential mediator of Notch activation, CSL is endowed with intrinsic transcription-repressive function and can be converted by other cofactors, besides NOTCH, into an activator (15, 16) . Evidence from various genetic models indicates that abrogation of CSL function can have consequences beyond suppression of Notch signaling, while conversely, NOTCH activation may involve other mediators besides CSL (15, 16) . In skin, the more pronounced phenotype of mice with keratinocyte-specific deletion of NOTCH1 and NOTCH2 genes versus CSL suggests that NOTCH has a broader function than CSL (17) . However, the converse possibility that CSL also plays a role distinct from that of NOTCH in keratinocytes and SCC development has not yet been addressed.
Epigenetic regulators impinge on the balance between cancer cell renewal and commitment to differentiation (18) . The cumulative mutation rate of this family of genes in SCCs is more than 50%, with a number of them involved in a squamous differentiation program (1) . Trimethylation of histone H3 at lysine 27 (H3K27me3) is a key histone modification, with transcription-repressive function that is deregulated in a variety of cancers (19) . Removal of H3K27me2 and H3K27me3 marks by the KDM6B (JMJD3) demethylase can operate in concert with NOTCH activation in cancer development, as indicated by the shared prooncogenic role of the 2 genes in T cell acute lymphoblastic leukemia (T-ALL) cells (20) . Like NOTCH, KDM6B is involved in key cellular processes, such as Notch 1/2 genes play tumor-suppressing functions in squamous cell carcinoma (SCC), a very common malignancy in skin and internal organs. In contrast with Notch, we show that the transcription factor CSL (also known as RBP-Jκ), a key effector of canonical Notch signaling endowed with intrinsic transcription-repressive functions, plays a tumor-promoting function in SCC development. Expression of this gene decreased in upper epidermal layers and human keratinocytes (HKCs) undergoing differentiation, while it increased in premalignant and malignant SCC lesions from skin, head/neck, and lung. Increased CSL levels enhanced the proliferative potential of HKCs and SCC cells, while silencing of CSL induced growth arrest and apoptosis. In vivo, SCC cells with increased CSL levels gave rise to rapidly expanding tumors, while cells with silenced CSL formed smaller and more differentiated tumors with enhanced inflammatory infiltrate. Global transcriptomic analysis of HKCs and SCC cells with silenced CSL revealed major modulation of apoptotic, cell-cycle, and proinflammatory genes. We also show that the histone demethylase KDM6B is a direct CSL-negative target, with inverse roles of CSL in HKC and SCC proliferative capacity, tumorigenesis, and tumor-associated inflammatory reaction. CSL/KDM6B protein expression could be used as a biomarker of SCC development and indicator of cancer treatment.
tinocytes (HKCs), expression of the CSL protein was substantially reduced with induction of differentiation by high-confluency conditions or suspension culture at times when a terminal differentiation marker such as involucrin was induced ( Figure 2A and Supplemental Figure 1D ). Downmodulation of CSL protein levels upon differentiation was likely due to a posttranscriptional mechanism, as CSL mRNA levels were increased rather than decreased ( Figure  2B and Supplemental Figure 1E ).
Relative to HKCs, CSL protein levels were increased in a panel of skin and oral SCC cell lines, independently of p53 status (The TP53 Web Site, http://p53.free.fr) (42) (Figure 2C ). mRNA levels were also higher in most of the tested cancer cell lines, indicating that CSL expression can be deregulated at both transcriptional and posttranscriptional levels ( Figure 2D) . A similar increase in CSL protein levels, with less consistent upregulation of mRNA levels, was also found in a panel of lung SCC cells relative to primary human bronchial epithelial cells (HBECs) (Figure 2 , E and F). Upregulation of CSL expression in SCC13 cells versus HKCs was also detected by immunohistochemical staining of these cells brought into suspension, using the same fixation and staining procedures utilized in the clinic for analysis of cytological specimens (Supplemental Figure 1F) .
CSL is a positive regulator of keratinocyte and SCC proliferative potential. To assess biological significance of the above findings, we evaluated consequences of modulated CSL expression in HKCs. Three independent strains were stably infected with a retrovirus expressing myc-tagged CSL, which in several previous papers was shown to be functionally equivalent to untagged CSL (43, 44) . A several-fold increase of CSL levels ( Figure 3A ), approximating that in SCC cells, resulted in significantly enhanced proliferative activity, as assessed by an assay for metabolically active cells (CellTiterGlo) ( Figure 3B ). Clonogenicity assays provide a well-established method to assess the fraction of keratinocytes with elevated proliferative potential (putative stem cells) (45) . Paralleling previous results, increased CSL expression significantly enhanced the fraction of HKCs with clonogenic capacities ( Figure 3C ).
Conversely, overall proliferation of HKCs was strongly suppressed by shRNA-mediated CSL gene silencing ( Figure 3 , D and E), associated with reduction of their clonogenic potential ( Figure 3F ). The sphere-forming capability of cells embedded in Matrigel was used as an additional measure of the proliferative potential of cells (46) . Strong inhibitory effects were also observed with this assay upon CSL silencing in all tested HKC strains ( Figure 3G ). Decreased proliferative potential of HKCs was paralleled by decreased DNA synthesis, as assessed by EdU labeling of cells ( Figure 3H ).
Like HKCs, SCC cell lines contain subpopulations with elevated proliferative potential (putative cancer stem cells), which can be assessed by clonogenicity assays (47) . Lentivirus-mediated increase of CSL expression significantly enhanced colony-and sphere-forming capability of a panel of SCC cell lines ( Figure  4 , A-C), while conversely, CSL gene silencing inhibited clonogenic potential and reduced overall proliferation (Figure 4 , D-F). Growth inhibitory effects of CSL gene silencing were not due to specific toxic mechanisms, as they were not observed with SCCO28 cells (Figure 4 , D-F), an oral SCC-derived cell line with advanced features of epithelial-to-mesenchymal transformation (48) . The sphere-forming capability of various SCC cell lines in cell-cycle control, senescence, and differentiation, and may play a role in cancer development in a context-dependent manner (21) (22) (23) . In fact, KDM6B expression is upregulated in several malignancies, such as Hodgkin's lymphoma (24) , breast cancer (25) , gliomas (26) , melanoma (27) , and renal cell carcinoma (28) , while it is suppressed in others, including lung adenocarcinoma and squamous cell carcinoma (29) , colon cancer (30, 31) , and liver and pancreatic cancers (32) . While inactivating KDM6B gene mutations are only found in 1%-3% of SCCs (cBioPortal for Cancer Genomics; http:// www.cbioportal.org), the gene, like NOTCH1, has been implicated as a positive determinant of squamous cell differentiation (33) .
Increased immune cell infiltration into tumors is a positive prognostic sign for elimination of cancer cells and favorable response to cancer immunotherapy (34) . In cells of the immune/ inflammatory systems, a crosstalk has been uncovered between KDM6B and NF-KB and STAT family members through a variety of mechanisms, including physical association (35) (36) (37) (38) . In contrast, mechanisms involved in the control of KDM6B in keratinocytes and SCC and possible interconnection with NOTCH/CSL signaling have not been investigated.
We report here that, in contrast with NOTCH activation, CSL has an intrinsic tumor-promoting function in SCC development that is mediated, in part, by suppression of KDM6B expression, a direct CSL target. Compared with CSL, KDM6B has an inverse effect on HKC and SCC proliferative capacity, tumorigenesis, and tumor-associated inflammatory reaction, and the 2 proteins could be used as prognostic markers of SCC development.
Results
CSL gene expression is reduced in differentiating keratinocytes and induced in premalignant and malignant cancer cells. CSL can play biologically significant roles as a repressor of transcription independently of NOTCH activation (15) . Control of CSL function in this context can occur through modulation of its expression (39, 40) . In human skin, immunofluorescence analysis showed that CSL is highly expressed in keratinocytes of lower epidermal layers, while it is substantially downmodulated in upper layers ( Figure  1A and Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/JCI96915DS1), in contrast with the opposite pattern of NOTCH 1/2 expression that we previously reported (41) . Similarly elevated CSL expression was also found in lower layers of oral epithelium, with pronounced downmodulation in upper layers ( Figure 1B) .
Actinic keratoses (AK) are premalignant SCC precursor lesions associated with an altered squamous cell differentiation program and expansion of cells of the proliferative compartment. Immunohistochemical analysis of these lesions showed pronounced upregulation of CSL expression relative to the surrounding normal epidermis ( Figure 1C and Supplemental Figure 1B ). Upregulated CSL expression was also found in dysplastic versus normal epithelium of the oral cavity, with a further increase in adjacent SCCs ( Figure 1D and Supplemental Figure 1C ). In parallel, immunohistochemical analysis of tissue arrays of skin and oral SCCs showed significantly greater CSL signal intensity in high-versus low-grade tumors ( Figure 1E ). These findings were mirrored by a pattern of CSL expression in cultured cells. In 3 independent strains of primary human kera-jci.org Volume 128 Number 6 June 2018
in immune-compromised mice (40) . CSL-overexpressing SCC cells formed rapidly expanding tumors, and mice were sacrificed at early times, in most cases prior to tumor formation by control cells injected in parallel ( Figure 5A ). Conversely, tumor formation by SCC cells was substantially delayed by CSL silencing and even in some cases totally suppressed ( Figure 5B ). Decreased tumor formation was mirrored by decreased cellular proliferation, as
Matrigel suspension was also suppressed by CSL silencing ( Figure  4G ), and decreased proliferation of SCC cells could be explained by decreased DNA synthesis as well as enhanced apoptosis (Supplemental Figure 2 , A and B). CSL promotes SCC tumor formation in a xenograft model. We next assessed the effects of CSL modulation on the tumorigenic potential of SCC cells utilizing an orthotopic ear-injection assay NOTCH1 and differentiation signature genes in HKCs (4), further consistent with a NOTCH separate function of CSL in these cells (Table 3 and Supplemental Table 2 ). In contrast, there was significant correlation between CSL-modulated genes and gene signatures of pathways implicated in inhibition of keratinocyte proliferation (specifically NF-κB and TGF-B) and inflammation ( Figure 7A and Table 3 ). Similar RNA-seq analysis was carried out in SCC13 cells with CSL gene silencing (GEO GSE102762). As with HKCs, many genes were deregulated upon CSL silencing in SCC13 cells, with a few hundred that were similarly modulated in both ( Figure 7B ). There was also high concordance in GO analysis, which showed that mitosis and DNA replication genes were among those downregulated by CSL silencing in SCC13 cells and that apoptosis genes were among those upregulated in response to CSL silencing (Tables 1 and 2, and Supplemental Table 1 ). GSEA also showed a similar positive correlation between the expression profiles of SCC13 cells with CSL gene silencing and gene signatures related to TGF-B, NF-κB, TNF-A, INF, and inflammatory responses, while there was again no significant association with NOTCH or keratinocyte differentiation gene signatures (Table 3 and Supplemental Table 2 ). Quantitative reverse-transcriptase PCR (RT-qPCR) assessed by Ki67 positivity ( Figure 6A ), and enhanced differentiation, as assessed by keratin 1 (K1) and K10 expression ( Figure 6 , B and C). Importantly, despite the lack of intrinsic effects on the proliferation of SCCO28 cells, CSL silencing also suppressed tumorigenicity of these cells, with decreased Ki67 positivity ( Figure 5B and Figure 6A ). The decreased tumorigenicity was accompanied in all cases by enhanced infiltration of immune cells together with a marked increase in expression of the proinflammatory cytokine IL6 (Supplemental Figure 3, A and B) .
CSL acts as a shared determinant of gene expression in HKCs and SCC cells. Independently of NOTCH activation, CSL plays a constitutive repressive function in gene transcription. By RNAsequencing (RNA-seq) analysis, more than 1,000 genes were consistently up-or downregulated in HKCs by CSL gene silencing (NCBI's Gene Expression Omnibus database; GEO GSE102762). Gene ontology (GO) analysis showed that gene families most significantly upregulated by CSL silencing are related to apoptosis and regulation of programmed cell death, while those most significantly downregulated are related to mitosis and DNA replication and repair (Tables 1 and 2 and Supplemental Table 1 ). By gene set enrichment analysis (GSEA) (49), we found no significant correlation between CSL-modulated genes and previously established GSE102762). In striking contrast to HKCs and SCC13 cells, only 36 genes were upregulated in SCCO28 cells upon CSL silencing and 4 were downmodulated. These genes belonged to families related to membrane/signaling, enzymes, extracellular matrix, and inflammatory/immunomodulatory cytokines, but none were directly involved in cell division control or apoptosis ( Figure 7F and Supplemental Table 1 ).
analysis confirmed downregulation of the panel of cell-cycle regulatory genes and upregulation of apoptotic and proinflammatory genes in HKCs and SCC13 cells as well as other SCC cells upon CSL silencing ( Figure 7 , C-E).
To probe into the consequences of CSL gene silencing in cancer cells that are resistant to its growth-inhibitory effects, similar RNA-seq analysis was carried out with SCCO28 cells (GEO IL6 was among the proinflammatory cytokines upregulated in SCC13, SCCO22, and SCCO28 cells with silenced CSL, consistent with increased IL6 expression found in small tumors formed by these cells by ear injection (Supplemental Figure 3B) . However, this could be a secondary event, as tumor formation by these assays took a relatively long time and, in a number of cases, cells with silenced CSL yielded no detectable tumors. An important question was therefore whether increased expression of IL6 and other coregulated cytokines occurs in SCC cells with silenced CSL even in vivo at early times preceding drastic differences in tumor formation. To address this point, we resorted to an alternative skin tumorigenicity assay, based on intradermal injection of cells embedded in Matrigel. Matrigel nodules form immediately after injection into animals and can be easily retrieved at any time. Parallel injections of SCC13 and SCCO28 cells with or without CSL gene silencing were used for these assays. Matrigel nodules retrieved at 1 week had sizes comparable to those of SCC cells with or without CSL silencing, with more detectable differences starting to occur at 2 weeks ( Figure 8A ). Histological features and inflammation, as detected by pan-keratin and CD45 staining, respectively, were comparable in all cases (Supplemental Figure 4, A and B) . To assess intrinsic differences in gene expression, we resorted to laser capture microdissection (LCM) of pan-keratin-positive SCC cells, followed by RTqPCR analysis. Results showed significant upregulation of IL6 and CCL20, a leukocyte chemotactic cytokine under positive IL6 control (50), in SCC13 and SCCO28 cells, with silenced CSL at both 1 and 2 weeks, with less consistent differences for 2 other cytokines, IL1-A and CXCL1 (Figure 8 , B and C).
Similar intradermal tumorigenicity assays were performed with SCC13 cells with increased CSL expression via lentiviral vector infection. At 2 weeks after injection, Matrigel nodules harboring SCC cells with increased CSL expression exhibited a notably larger size than controls ( Figure 8D ), in agreement with previous results obtained by ear-injection assays. Histological features and inflammation were also comparable in all cases (Supplemental Figure 4 , C and D). LCM and RT-qPCR analysis at both 1 and 2 weeks revealed significant reduction of IL6 and CCL20 expression in SCC cells with increased CSL, mirroring the inverse effects of CSL gene silencing ( Figure 8E ). Differences in expression of IL1-A and CXCL1 were again less consistent ( Figure 8E ). , and SCCO28 cells infected with CSL-silencing lentivirus versus empty vector control were injected into ears of NOD/SCID mice. Shown are tumor volumes (upper panels) with representative images of 1 pair of mouse ears (lower panels), and corresponding H&E staining of SCCO22 lesions (right panels). Scale bars: 250 μm. n = 6 mice for SCC13 lesions; n = 6 mice for SCCO22 lesions; n = 6 mice for SCCO28 lesions from experiment 1 (Exp.1) and 5 mice from experiment 2. (A and B) Scale bars: 250 μm. Data are shown as mean ± SEM. *P < 0.05; ***P < 0.0005, 1-tailed paired t test. jci.org Volume 128 Number 6 June 2018
sites of the KDM6B locus ( Figure 9C ) and to the HES1 promoter as a positive control ( Figure 9D ). Upregulation of the KDM6B gene by CSL gene silencing was confirmed by RT-qPCR in HKCs and SCC cells analyzed in this study, including SCCO28 cells ( Figure  10 , A and B). Upregulation of the KDM6B protein was also found by immunofluorescence analysis of HKCs and SCC cells with silenced CSL (Figure 10C ). Even in vivo, in intradermal Matrigel assays described above, KDM6B expression was pronouncedly upregulated in SCC13 and SCC028 cells with silenced CSL ( Figure  10D ). Conversely, KDM6B expression was found to be downregulated by LCM and RT-qPCR analysis of AK and SCC lesions versus flanking normal epidermis ( Figure 10E ). To assess functional significance of KDM6B upregulation, HKCs were infected with retroviral vectors overexpressing KDM6B in WT versus demethylase-defective mutant forms (33) in parallel with empty vector control. Expression of functionally active KDM6B, but not the inactive form, was sufficient to KDM6B as direct target and mediator of CSL regulatory function in keratinocyte/SCC proliferation and tumorigenesis. For further mechanistic insights, we sought to identify direct CSL targets whose upregulation by CSL gene silencing could impinge on cell proliferation and tumor formation. Out of several hundreds of CSL target genes identified by ChIP-seq analysis (GEO GSE102761) (Supplemental Table 3 ), 68 were found by RNA-seq to be significantly upregulated by silencing of the gene in HKCs ( Figure 9A ). These coded for enzymes involved in signal transduction and metabolism, secreted factors, and cell surface and cytoskeletal proteins as well as transcription factors and chromatin modifiers ( Figure 9B) . Out of these genes, 13 were also upregulated by CSL silencing in SCC13 cells, including HES1, a "canonical" NOTCH/CSL target variously implicated in keratinocytes (4, (51) (52) (53) , and KDM6B, a histone H3-K27 demethylase with contextdependent functions in cancer development (22) (Figure 9B ). Direct ChIP assays on HKCs confirmed CSL binding to multiple Thus, KDM6B is a direct CSL-negative target with an inverse opposite role in control of HKC and SCC proliferative capacity, tumorigenesis, and tumor-associated inflammatory reaction.
Discussion
Proliferation and differentiation of squamous epithelial cells are tightly regulated through integrated signaling networks, with NOTCH activation as a critical player (1, 2). We show here that, besides its role as a mediator of NOTCH activation, CSL has another and opposite function in SCC development. In contrast to NOTCH, CSL levels are inversely correlated with keratinocyte differentiation and are already upregulated at premalignant stages of skin and oral SCC development. This is of functional significance, as increased CSL expression enhances keratinocyte and SCC proliferation potential and tumor formation, while CSL downmodulation suppresses them.
reproduce the inhibitory effects of CSL silencing on cellular proliferation and colony formation in 3 different HKC strains (Figure 11, A and B) . Conversely, silencing of KDM6B counteracted growth-inhibitory effects of CSL knockdown in SCC13 and, to a lesser extent, in SCCO22 cells ( Figure 11C ). Overall colonyforming capability was increased in cells with dual silencing of CSL and KDM6B genes relative to cells with CSL silencing alone ( Figure 11D ), with particular increases in colonies of larger size, thought to originate from cells with greater proliferative capacity (45) (Figure 11E) . At the gene-expression level, counteracting effects were detected upon concomitant silencing of CSL and KDM6B on key cell-cycle and proinflammatory genes (such as CCNB1, CDK1, and IL6), with no effects on others (such as CCND1, CASP8, or BID) ( Figure 11F ), pointing to KDM6B as a main, but not the only, mediator of CSL-silencing effects on gene transcription.
A key question was to what extent KDM6B upregulation is involved in the tumor suppression that CSL silencing exerts in vivo. Accordingly, 3 different SCC cell lines (SCC13, SCCO22, and SCCO28) with shRNA-mediated silencing of CSL individually and in combination with KDM6B knockdown were injected into ears of immune-compromised mice. As shown in Figure 12A , the size of cancer lesions was dramatically enhanced by dual silencing of While increased CSL expression enhanced the proliferative potential of primary HKCs and various SCC cell lines, its silencing exerted opposite effects. Growth-inhibitory effects of CSL gene silencing can be explained by downregulation of positive regulators of the cell cycle, consistent with the thinner epidermis and reduced proliferation previously reported in mice with keratinocyte-specific deletion of the CSL gene (53) . The further widespread alterations in the skin of these mice were attributed to skin barrier defects associated with strong induction of thymic stromal lymphopoietin (TSLP) cytokine production (7, 58) . TSLP deregulation may be a peculiarity of the murine system, as it was not observed in human primary keratinocytes and SCC cell lines upon CSL gene silencing. Nevertheless, other cytokines and chemokines with potent proinflammatory function were instead consistently induced, particularly IL6, a pleiotropic regulator of the immune and inflammatory systems (59) that has cell-autonomous growthinhibitory function (59, 60) , and CCL20, a leukocyte chemotactic factor under positive IL6 control (50) . Importantly, expression of these cytokines was enhanced in all SCC cells with CSL silencing and also in vivo, in an early assay of SCC development preceding differences in tumor size and inflammation. As such, expression of these cytokines is an intrinsic rather than a secondary event of decreased CSL expression in SCC cells. This can have a pleiotropy of functions at early versus late stages of tumor development, when substantially increased inflammatory reaction was found in association with tumor suppression. An increased immune-cell infiltration into tumors is a sign of a favorable response to checkpoint inhibitors (34) , and it will be interesting to assess whether the regulatory network that we have uncovered correlates with immune infiltration in SCCs and/or their response to therapy.
Consequences of changes in CSL levels can be ascribed, in part, to direct negative control of the histone demethylase KDM6B gene, which impinges on genes with key cell-cycleregulatory and proinflammatory functions (23) . This gene is essential for life after birth, as knockout mice are born smaller and die perinatally due to respiratory failure (21, 61, 62) . Previous studies have pointed to a potential tumor-suppressive role of KDM6B in specific tissues (such as lung, colon, and pancreas) (30) (31) (32) 63) , while in others (such as blood, breast, and brain) it may play an opposite tumor-promoting function (24) (25) (26) . This demethylase is an important player at the intersection between cellular senescence and cancer (22, 29) , and it also positively regulates epidermal differentiation (33) . Interestingly, the KDM6B gene is located on chromosome 17 in close vicinity to the p53 tumor-suppressor gene, with allelic loss at this position occurring in a variety of cancers, including SCCs (1, 22, (64) (65) (66) .
A number of direct CSL target genes commonly upregulated by its silencing in HKCs and SCC13 cells could be involved in the In Drosophila, it has long been known that the role of Su(H) (CSL homologue) as mediator of NOTCH activation cannot explain the different phenotypes resulting from loss of either gene (14) (15) (16) . Increasing evidence indicates that, also in mammalian systems, CSL and NOTCH play only partially overlapping functions. In specific contexts, such as in conversion of stromal fibroblasts into cancer-associated fibroblasts (CAFs), loss or downmodulation of CSL, rather than recapitulating loss of NOTCH effects, can trigger the same response as NOTCH activation (40) .
The possibility of distinct roles of CSL and NOTCH in cancer cells has been investigated to a very limited extent, with apparently conflicting results. A recent study focused on breast cancer and Burkitt lymphoma, in which NOTCH acts as an oncogene, pointed to an opposite tumor-suppressive role for CSL (54) . Specifically, CSL silencing in MDA-MB-231 human breast cancer and DG75 Burkitt lymphoma cells enhanced tumor growth, with c-MYC-and NF-KB-dependent increases in cell survival. However, an opposite conclusion was suggested by other studies with cultured cancer cell lines, including one that was also with MDA-MB-231 cells (55) (56) (57) . Thus, the possibility of distinct roles of NOTCH and CSL in specific cancer types needs further assessment in the context of their cells of origin and tumor microenvironment. The present work represents such an attempt, as it relates to primary keratinocytes and SCC.
We have found that in normal skin and oral epithelia, CSL expression is inversely related to differentiation. Complex posttranscriptional mechanisms are likely involved, at least in differentiating primary keratinocytes in which downmodulation of CSL protein levels was associated with increased (rather than decreased) mRNA expression. Perturbed differentiation is a key feature of squamous cancer development (1). Consistently, increased CSL levels were already found in premalignant skin and oral SCC lesions and SCC cells. While parallel increases of CSL mRNA and protein levels were detected in some SCC cells, in others, only the protein was upregulated. Posttranscriptional control of CSL expression and function is a complex and poorly understood topic currently under investigation. Here, we focused on the functional significance of changes in CSL levels in skin and head and neck epithelial cells. of KDM6B by NF-KB and STATs observed in other cell types (36, 38, 70, 72, 73) may also apply to squamous cancer, which is often associated with and can be induced by inflammation (74) . Targeting epigenetic regulators is emerging as promising cancer therapy. Pharmacological inhibitors of KDM6B (such as GSK-J4) (75) were shown to inhibit growth of different cancer cell lines, such as T-ALL and glioma (20, 21, 76, 77) , in which KDM6B plays an oncogenic role (22) . While use of these compounds would obviously be contraindicated for squamous cancer, other drugs enhancing KDM6B function or inhibiting epigenetic modifying enzymes with an opposite role could be of benefit and open novel windows of opportunity for both prevention and treatment of this disease.
More generally, our findings could lead to valuable prognostic tools to be used, in combination with other markers, in the clinic. This is suggested by a significant association between increased CSL expression and high-grade SCCs in tissue microarrays (Figure 1E ) and detectable differences in expression of this protein in normal keratinocytes versus SCC cells processed as for analysis observed biological effects. Among these, KDM6B was the only epigenetic regulator with potential global impact on gene transcription. KDM6B upregulation is of functional relevance, as its silencing counteracted growth-inhibitory effects of CSL knockdown in SCC cells, both in vitro and in vivo. Mechanistically, this could be explained by the previously reported role of KDM6B in direct transcriptional control of cell-cycle-inhibitory genes, such as CDKN2A (22, 29) , differentiation genes, such as K1 (33) , and cytokines with proinflammatory functions, specifically IL6 (35, 37) . Consistent with the latter mechanism of action, we found that upregulation of IL6 expression by CSL silencing was suppressed by concomitant KDM6B knockdown, which parallels its in vivo effects in rescuing tumor formation.
There are several possible mechanisms by which KDM6B can regulate the above genes. KDM6B can directly associate with key transcription factors, such as p53 (67, 68) , p65, and p50 NF-KB subunits (37) and STAT (69, 70) and SMAD (71) family members, enhancing their functions. In turn, a reciprocal mode of regulation Table 3 . (B) Venn diagram illustrating number of up-and downregulated genes overlapping in RNA-seq profiles of HKCs and SCC13 cells upon CSL silencing. (C) Three independent HKC strains infected with 2 shRNA lentiviruses against CSL were analyzed by RT-qPCR for indicated genes with 36B4 for normalization. n = 3 HKC strains. (D) SCC13 cells infected with 2 shRNA lentiviruses against CSL were analyzed by RT-qPCR for indicated genes using 36B4 for normalization. n = 3 independent experiments. Data are shown as mean ± SEM. (E) Panel of SCC cell lines infected with 2 shRNA lentiviruses against CSL were analyzed by RT-qPCR for indicated genes using 36B4 for normalization. n = 3 independent experiments. Data are shown as mean ± SEM. (F) List of genes upregulated by RNA-seq analysis in SCCO28 cells upon CSL gene silencing divided by biological function. ECM, extracellular matrix; TF, transcription factors. (C-E) *P < 0.05; **P < 0.005; ***P < 0.0005, 2-tailed 1-sample t test followed by Benjamini-Hochberg correction. jci.org Volume 128 Number 6 June 2018
Methods
Cells and human samples. Normal epithelial cells and SCC cells were cultured as previously described (12, 78) . Oral SCC cells (SCCO11, SCCO13, SCCO22, and SCCO28) were provided by James Rocco (Massachusetts General Hospital, Boston, Massachusetts, USA). Oral SCC cells (Cal27, Cal33, and FaDu) were provided by Genrich Tolstonog of cytological specimens. Similar assessment of KDM6B expression in clinical settings should also be possible with development of adequate antibodies. These are worthwhile goals, as there is an unmet need for biomarkers that help identify precancerous and cancerous squamous cancer lesions and predict their response to novel modalities of treatment. . (E) RNA samples from LCM-captured material were examined by RT-qPCR for cytokine marker expression. n = 5 mice at week 1; n = 5 mice at week 2. (C and E) Data are shown as mean ± SEM. *P < 0.1; ***P < 0.001, 1-tailed 1-sample t test followed by Benjamini-Hochberg correction. jci.org Volume 128 Number 6 June 2018 mids and our plasmid of interest using Jetpei (Polyplus) transfection reagent for 6 hours, followed by virus collection after 48 hours. HKCs and SCC cells were infected for 1 hour and 6 hours, respectively, with high-titer lenti-and retroviruses sufficient to infect the majority of cells. Two days after infection, cells were selected with 1 μg/ml of puromycin for 3 days for shCSL and MSCV-KDM6B, with 500 μg/ml of G418 for 4 days for pmx-mycCSL and pIND20-mycCSL, and with 10 μg/ml of blasticidin for 4 days for shKDM6B. Lentiviral vectors encoding shRNA against KDM6B were purchased from OriGene (HC141378B and HC141378C). Retroviral vectors encoding WT and mutant KDM6B (MSCV-KDM6B) (Addgene plasmid nos. 21212 and 21214) were a gift from Paul Khavari (Stanford University, Stanford, California, USA). Plasmids encoding for shCSL, pMXs-myc-CSL, and pINDUCER-20-myc-CSL have been previously described (40) .
Cell assays. For proliferation assays, cell viability was assessed using the CellTiter-Glo Kit (Promega) by luminescence intensity determination over time. In brief, cells were plated onto 96-well plates (1,000 cells/well; triplicate wells/condition) 5 days after infection for shCSL and MSCV-KDM6B, 6 days after infection for pMXs-myc-CSL and shKDM6B, and 2 days after doxycycline treatment (500 ng/ml) for pIND20-mycCSL. Equal volumes of CellTiter-Glo reagent (50 μl) and (CHUV). Skin SCC cells (SCC12 and SCC13) were provided by James Rheinwald (Brigham and Women's Hospital, Boston, Massachusetts, USA). Lung SCC cells (H520, H2170, HCC95, SW900, and SK-MES-1) were provided by Peter Hammerman (Dana-Farber Cancer Institute, Boston, Massachusetts, USA). HBECs were purchased from ATCC. HKC cells were prepared from discarded human foreskin samples from circumcision at the Department of Pediatrics (CHUV). In brief, skin tissue was immersed in 1% Dispase II (Roche) overnight at 4°C, and the epidermis compartment was separated from the dermis. Then, epidermis was minced and digested by 0.25% Trypsin-EDTA (Gibco, Thermo Fisher Scientific) for 1 hour at 4°C with gentle agitation, followed by filtering through 40 μm mesh. After enzymatic digestion was terminated by adding a volume of serum-containing media that was equal to the volume of the reaction, cell pellets were collected by centrifugation, plated, and cultured as previously described (41) . Excised human AK samples not used for histological analysis were provided by Renato Panizzon, and human SCC samples were provided by Massimo Bongiovanni. Human SCC tissue arrays were purchased from US Biomax (SK2081 and OR802).
Cell manipulations and plasmid constructs. Conditions for culturing cells and viral infections were as previously reported (12, 40, 78) . Briefly, HEK293 cells were cotransfected with viral packaging plas- polymerize. Cells were brought into suspension in normal culture medium plus 1% Matrigel and plated for 8 days onto a precoated chamber. For EdU assays, DNA synthesis was assessed using the Click-iT Plus EdU Imaging Kit (Life Technologies). Cells were incubated for 6 hours with 10 μM EdU-labeling solution in prewarmed tissue culture medium. Cells were then fixed with 4% formaldehyde, followed by permeabilization with 0.5% Triton-X 100. After permeabilization, cells were incubated with Click-iT Plus Reaction Cocktail for 30 minutes at RT, followed by counterstaining with DAPI.
For apoptosis assays, dead and preapoptotic cells were assessed using the Aqua Vivid Kit (Invitrogen) and the Annexin Kit (BD Bioscicell culture medium (50 μl) were added to cells, followed by induced cell lysis on an orbital shaker for 3 minutes. The plate was incubated at room temperature (RT) for 10 minutes, after which luminescence was recorded using the Molecular Device Spectra Max Fluorometer.
For clonogenicity assays, cells were plated on 60 mm dishes (1,000 cells/well; triplicate wells/condition) and cultured for 10 days. Colonies were fixed with 4% formaldehyde and stained with 1% crystal violet.
For spheroid assays, cells were plated onto 8-well chamber slides coated with Matrigel (BD Biosciences). In brief, 8-well chambers were coated with 50 μl Matrigel per well and incubated for 30 minutes to Figure 8C were examined by RT-qPCR for KDM6B expression. Data are shown as mean ± SEM, 1-tailed 1-sample t test. n = 4 mice for SCC13 at week 1; n = 5 mice for SCC13 at week 2; n = 5 mice for SCCO28 at week 1; n = 4 mice for SCCO28 at week 2. (E) LCM-obtained epidermis from AK and skin SCC lesions versus flanking normal skin were analyzed by RT-qPCR for KDM6B expression. P, patients. n = 6 AK regions; n = 6 normal regions; n = 2 SCC regions; n = 2 normal regions. (A-E) *P < 0.05; **P < 0.005; ***P < 0.0005, 2-tailed paired t test. jci.org Volume 128
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Tumorigenesis experiments. Intradermal ear-injection assays were carried out in 6-to 8-week-old NOD/SCID mice with IL-2 receptor γ chain null mutation (University of Lausanne). For in vivo silencing assays, SCC cells were infected with either control or shCSL viruses for 5 days and injected in equal number (2 × 10 5 cells per injection)
into left and right ears of each mouse. For in vivo dual silencing assays, SCC cells were first infected with either control or shKDM6B retroviruses for 6 days, followed by infection with shCSL lentiviruses for 5 days before injection into mouse ears (2 × 10 5 cells per injection).
For in vivo overexpression assays, SCC cells were infected with either control or pIND20-mycCSL viruses and injected in equal number (2 × 10 5 cells per injection) into left and right ears of each mouse.
Doxycycline (1 mg/ml) was freshly added to drinking water (containing 5% sucrose) every other day. In all cases, cells were concentrated ences), respectively. In brief, cells were harvested and incubated for 30 minutes on ice using the Aqua Dead Cell Stain Kit (Thermo Fisher Scientific). Cells were then washed with annexin-binding buffer, followed by incubation for 15 minutes at RT with annexin-Cy5 dye for staining of preapoptotic cells. Following annexin incubation, cell were fixed with 4% formaldehyde and counterstained with DAPI. For gene expression, cells were collected for RNA followed by RTqPCR analysis. Total RNA (1 μg) was reverse-transcribed into cDNA using RevertAid H Minus Reverse Transcriptase (Thermo Scientific). Real-time qPCR was then done using SYBR Fast qPCR Master Mix (Kapa Biosystems) in Light Cycler 480 (Roche) according to the manufacturer's protocols. All RNA samples were analyzed in triplicate with gene-specific primers and 36B4 for normalization. The list of primers is provided in Supplemental Table 4 . The same HKC strains as in A were plated at a limited density, and colony formation was measured. Data are shown as mean ± SD. n = 3 biological replicates/strain. (C) SCC13 and SCCO22 cells were infected with shRNA lentivirus against KDM6B or empty control, followed by infection with either control or CSL-silencing lentiviruses. Cells were tested for cell metabolic activity assays over the indicated days. Data are shown as mean ± SEM. n = 3 independent experiments. (D) The same cells as in C were plated at a limited density, and colony formation was measured. Data are shown as mean ± SEM. n = 3 independent experiments. (E) The same colony dishes as in D were assessed for the number of large colonies. (F) The same SCC13 cells as in C were analyzed by RT-qPCR for the indicated genes using 36B4 for normalization. Data are shown as mean ± SEM. Two-tailed unpaired t test, followed by Benjamini-Hochberg correction. n = 3 independent experiments. (A-E) *P < 0.1; **P < 0.01; ***P < 0.001, 1-way ANOVA with Tukey's test. jci.org Volume 128 Number 6 June 2018 GSEA for RNA-seq expression profiles were performed using GSAA-SeqSP software (gene set association analysis for RNA-seq data with sample permutation) (79) from the Gene Set Association Analysis (GSAA) platform (version GSAA_2.0, http://gsaa.unc.edu/). Curated gene sets were obtained from the Molecular Signatures Database (MSigDB v5.2; http://www.broadinstitute.org/gsea/msigdb/). Gene sets tested in this study are listed in Supplemental Table 2 .
ChIP-seq and ChIP-tagmentation. ChIP assays with antibody against CSL versus nonimmune IgG control were performed as previously described (40), followed by assessment of fold enrichment for indicated sites. Primer sequences and antibodies used in this assay are listed in Supplemental Tables 4 and 5 Table 3 . For ChIP-tagmentation, DNA was immunoprecipitated from 1 × 10 6 HKCs using 10 μl CSL antibody per 10 6 cells. Chromatin was tagged with Tn5 transposase (Illumina), followed by decrosslinking, purification, and amplification (14 cycles) using tag-specific primers. Amplified products were diluted 10 times, and 1 μl was used for qPCR to determine fold enrichment at indicated sites. Accession numbers. The RNA-seq and ChIP-seq data sets generated for this study were deposited in the NCBI's Gene Expression Omnibus database (GEO GSE102762 and GSE102761).
Statistics. Data are presented as mean ± SD or mean ± SEM among controls and experimental groups, as indicated in the figure legends. Statistical significance between controls and experimental groups was assessed by Student's t test (with Benjamini-Hochberg correction where needed) or 1-way ANOVA (with Dunnett's or Tukey's test), as indicated in the figure legends. *P < 0.05 was considered statistically significant (unless otherwise indicated).
Study approval. All mouse work was carried out according to Swiss guidelines for the use of laboratory animals, with protocols approved by the veterinary office of Canton de Vaud. All excised human samples were used with the approval of the University of Lausanne and CHUV. Informed consent was obtained as required.
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DAL and SHJ performed experiments and contributed to the analysis of results. PO conducted bioinformatics analysis. CS, MB, and by centrifugation and resuspended in 3 μl of medium per ear injection using a 33-gauge microsyringe (Hamilton). Mice were sacrificed for tissue analysis 5 to 8 weeks later, after the injection.
Intradermal back-injection assays were carried out in 6-to 8-week-old NOD/SCID mice with IL-2 receptor γ chain null mutation (University of Lausanne). SCC cells were infected with the virus of interest, brought into suspension, and admixed with 70 μl Matrigel (BD Biosciences), followed by injection of equal numbers (10 6 cells per injection) into left and right sides of the mouse back. Mice were sacrificed for tissue analysis 1 week and 2 weeks after injection. Tumor size was measured using a digital caliper, and volume was calculated using the following formula: volume = length × width × height.
Immunodetection techniques. Conditions for immunoblotting, immunofluorescence, and immunohistochemistry were as previously reported (74) . The list of antibodies is provided in Supplemental Table 5 . Scans of the full uncut immunoblots are shown in Supplemental Figure 5 .
For immunofluorescence, cells were fixed with 4% paraformaldehyde and permeabilized in 0.1% Triton X-100, followed by blocking in 5% donkey serum in PBS. Primary antibodies were incubated at 4°C overnight, followed by PBS washes, then incubated with secondary antibodies at RT for 1 hour and mounted in Fluoromount Mounting Medium (MilliporeSigma) after nuclear DAPI staining. Immunofluorescence images were acquired with a Zeiss LSM700 Meta laser-scanning microscope.
For immunofluorescence-guided LCM, frozen tissues were freshly cut and immediately fixed with 75% ethanol for 30 seconds. Sections were then briefly blocked in 10% donkey serum in PBS for 2 minutes, followed by incubation with Alexa Fluor 488-conjugated antibodies and propidium iodide (MilliporeSigma) for 2 minutes. Sections were washed by rinsing in PBS, then air-dried before processing using the Arcturus XT Microdissection System (Applied Biosystems).
For immunohistochemistry, cells were fixed with acetone for 3 minutes, followed by blocking of endogenous peroxidase by peroxidase-blocking solution (3% H 2 O 2 in PBS) for 10 minutes. Cells were further blocked in 10% goat serum in PBS for 10 minutes. Primary antibodies were incubated for 1 hour at RT, followed by PBS washes, then incubated with secondary antibodies for 30 minutes at RT. Cells were then incubated for 3 minutes with DAB solution, followed by counterstaining for 4 seconds with Harris Haematoxylin (Leica Biosystems).
For signal quantification, acquired images for each color channel were imported into ImageJ software and converted into binary images. Intensity was measured using "measurement" or "particle analysis" in areas of interest. All measurements were exported as Microsoft Excel files.
RNA-seq and GSEA. RNA-seq analysis was performed as follows. Total RNA was extracted 5 days after shRNA infection for CSLsilencing cells using Direct-zol RNA Miniprep Kit (Zymo Research). Library preparation using TruSeq Kit (Illumina) was done with 4 μg of total RNA. Single read was done on an Illumina HiSeq 2000 sequencer at the Genomic Facility (University of Lausanne). Reads were trimmed by using Trimmomatic (v0.22; http://www.usadellab.org/cms/ ?page=trimmomatic), followed by mapping to the human hg19 reference genome using TopHat (v2.0.8b; https://ccb.jhu.edu/software/ tophat/index.shtml). Gene-expression levels were then evaluated using the HTSeq package (release 0.5.4p1; https://htseq.readthedocs. io/en/release_0.9.1/). The DeSeq2 package (https://bioconductor.org/ packages/release/bioc/html/DESeq2.html) was used to normalize
